ANI Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.8%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$1.1Bnext fiscal year
FY EPS (est.)
$9.29next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 6 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cortrophin Gel Net Revenue Quarterly75.1M
Total Net Revenue Quarterly237.5M
Adjusted Non-GAAP EBITDA Quarterly63M
Watch Items
- Estradiol Gel Class II RecallTrigger: Any expansion of the voluntary recall beyond the initial 3,964 cartons or FDA warning lettersAction: Assess impact on generic segment gross margins and potential manufacturing compliance costs
- Customer Concentration RiskAction: Evaluate distributor purchasing leverage and potential credit risk exposure
- Iluvien Retina Franchise RecoveryAction: Review commercial execution, peer-to-peer education initiatives, and patient assistance program funding
Research as of 20 Jun 2026